Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
CAMBRIDGE, Mass., Nov. 09, 2016 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview at the Stifel Healthcare Conference 2016 on Wednesday, November 16, 2016, at 10:15 a.m. ET in New York City.
A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
